Pharmaceutical Price Transparency Should Be Policy Goal - Schondelmeyer
Executive Summary
Policy making efforts should focus on pharmaceutical price transparency as a method to lower drug costs, PRIME Institute Director Stephen Schondelmeyer, PhD, told the HHS conference on drug pricing Aug. 8 in Washington, D.C.